Press Releases

December 2, 2018 —BOSTON, MA. and STOCKHOLM, SWEDEN, November 30, 2018 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the closing of a EUR 50 million Series C financing round led by the
June 17, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm ORR (by IWG) of 100% in all evaluable
April 16, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago   ORR (by IWG) of 100% in all